Shares of Diploma PLC (LON:DPLM – Get Free Report) hit a new 52-week high during mid-day trading on Tuesday. The stock traded as high as GBX 7,960 and last traded at GBX 7,960, with a volume of 2288952 shares changing hands. The stock had previously closed at GBX 7,870.
Analyst Ratings Changes
DPLM has been the subject of a number of recent research reports. Berenberg Bank reaffirmed a “buy” rating and set a GBX 9,000 price objective on shares of Diploma in a research report on Monday, July 20th. Royal Bank Of Canada restated an “outperform” rating and set a GBX 7,400 price target on shares of Diploma in a research note on Tuesday, September 8th. Finally, JPMorgan Chase & Co. increased their price target on Diploma from GBX 5,760 to GBX 8,250 and gave the stock an “overweight” rating in a report on Monday, August 24th. Six investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of GBX 7,400.
Check Out Our Latest Analysis on DPLM
Diploma Price Performance
Insider Buying and Selling
In other news, insider Katie Bickerstaffe acquired 246 shares of Diploma stock in a transaction that occurred on Wednesday, September 23rd. The stock was purchased at an average cost of GBX 7,696 per share, with a total value of £18,932.16. Also, insider Mandy Gradden purchased 1,000 shares of the company’s stock in a transaction dated Friday, July 17th. The stock was purchased at an average price of GBX 7,183 per share, with a total value of £71,830. Over the last ninety days, insiders bought 1,850 shares of company stock valued at $13,340,934. 1.14% of the stock is owned by insiders.
Diploma Company Profile
Diploma PLC, together with its subsidiaries, supplies specialized technical products and services in the United Kingdom, Continental Europe, North America, and internationally. It operates through three business sectors: Life Sciences, Seals, and Controls. The Life Sciences sector supplies technology-enabled products used in surgical procedures in operating theatres and endoscopy; testing equipment and services for clinical laboratories; and bio-pharma, food safety and testing, and other research-oriented products.
Featured Stories
- Five stocks we like better than Diploma
- Skydance Just Became a Media Giant—With an $80 Billion Debt Load
- Could Velo3D Be the Next Defense Buyout Target?
- Penguin Solutions Is Soaring as AI Memory Demand Explodes
- Alphabet’s Chart Is Coiling—and the Fundamentals May Be Ready to Back It Up
Receive News & Ratings for Diploma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diploma and related companies with MarketBeat.com's FREE daily email newsletter.
